TherapeuticsMD (TXMD) Tops Q3 EPS by 5c

TherapeuticsMD (NASDAQ: TXMD) reported Q3 EPS of ($0.16), $0.05 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $3.5 million versus the consensus estimate of $4.43 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
• Hawaiian Electric trades at 8.8x P/E, but wildfire risk clouds value case
• S&P Global completes sale of energy software portfolio to SLB